Skip to main content
    O

    Organon & Co (OGN)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $13.91
    +0.01 (+0.07%)

    Market Cap: $3.65B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Organon & Co (OGN) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Organon (OGN) to earn $3.44 per share in the fiscal year ending Dec 31, 2026, on revenue of $6.16B. Of 5 analysts, 0 rate the stock Buy or Strong Buy, 4 Hold and 1 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 3.40, inside the Hold band from 2.5 up to 3.5. Sell and Strong Sell make up 20% of the ratings.

    RatingAnalystsShare
    Strong Buy00.0%
    Buy00.0%
    Hold480.0%
    Sell00.0%
    Strong Sell120.0%
    Consensus
    Hold
    Total analysts
    5

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus rises 6.1% and revenue estimates rise 2.1%.

    Fiscal year ending Dec 31, 2026
    $3.44
    EPS consensus, revenue $6.16B
    Fiscal year ending Dec 31, 2027
    $3.65
    EPS consensus, revenue $6.29B
    Next report
    Feb 10, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$3.44$3.30 to $3.724$6.16B$6.13B to $6.17B3
    Dec 31, 2027$3.65$3.55 to $3.824$6.29B$6.24B to $6.36B3

    Quarterly Estimates

    The EPS consensus rises from $0.80 for the quarter ending Dec 31, 2026 to $0.92 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$0.80$0.64 to $0.979$1.56B$1.51B to $1.62B6
    Mar 31, 2027$0.92$0.90 to $0.942$1.53B$1.53B to $1.53B1

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 0 upward and 3 downward EPS revisions. Cuts outnumber raises in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202601
    Fiscal year ending Dec 31, 202701
    Quarter ending Mar 31, 202701

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 5.0% from $3.62.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$3.44$3.36$3.43$3.43$3.62-5.1%
    Fiscal year ending Dec 31, 2027$3.65$3.62$3.62$3.62$3.64+0.3%
    Quarter ending Mar 31, 2027$0.92$0.88$0.88$0.88$0.88+5.0%

    Frequently Asked Questions About OGN

    What is the OGN stock forecast?

    Consensus analyst estimates put Organon's EPS at $3.44 for the fiscal year ending Dec 31, 2026, on revenue of $6.16B. The consensus rating from 5 analysts is Hold.

    How do analysts rate OGN stock?

    Of 5 analysts covering Organon, 0 rate it Strong Buy, 0 Buy, 4 Hold, 0 Sell and 1 Strong Sell, for a consensus of Hold.

    What EPS do analysts expect from OGN next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $3.44, with estimates from $3.30 to $3.72 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $3.65, with estimates from $3.55 to $3.82 from 4 analysts.

    What revenue do analysts expect from Organon next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $6.16B, with estimates from $6.13B to $6.17B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $6.29B, with estimates from $6.24B to $6.36B.

    How many analysts cover OGN?

    5 analysts rate Organon stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.